Business Description
Hyundai Bioscience Co Ltd
SIC : 111
ISIN : KR7048410005
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.13 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.42 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 62.21 | |||||
Beneish M-Score | -3.8 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.8 | |||||
3-Year EBITDA Growth Rate | -56.2 | |||||
3-Year EPS without NRI Growth Rate | -17.2 | |||||
3-Year FCF Growth Rate | 30.4 | |||||
3-Year Book Growth Rate | -7.9 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.66 | |||||
9-Day RSI | 49.1 | |||||
14-Day RSI | 47.66 | |||||
6-1 Month Momentum % | -34.46 | |||||
12-1 Month Momentum % | -0.49 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.18 | |||||
Quick Ratio | 1.81 | |||||
Cash Ratio | 1.7 | |||||
Days Inventory | 206.86 | |||||
Days Sales Outstanding | 58.12 | |||||
Days Payable | 47.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 53.17 | |||||
Operating Margin % | -103.2 | |||||
Net Margin % | -152.92 | |||||
FCF Margin % | -69.57 | |||||
ROE % | -26.94 | |||||
ROA % | -23.49 | |||||
ROIC % | -20.46 | |||||
ROC (Joel Greenblatt) % | -169.91 | |||||
ROCE % | -27 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 84.24 | |||||
PB Ratio | 17.68 | |||||
Price-to-Tangible-Book | 56.74 | |||||
EV-to-EBIT | -54.38 | |||||
EV-to-EBITDA | -60.31 | |||||
EV-to-Revenue | 83.73 | |||||
EV-to-FCF | -118.91 | |||||
Price-to-Median-PS-Value | 10.14 | |||||
Price-to-Net-Current-Asset-Value | 104.7 | |||||
Price-to-Net-Cash | 186.46 | |||||
Earnings Yield (Greenblatt) % | -1.83 | |||||
FCF Yield % | -0.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Hyundai Bioscience Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 9,481.385 | ||
EPS (TTM) (â‚©) | -366 | ||
Beta | 0.02 | ||
Volatility % | 50.45 | ||
14-Day RSI | 47.66 | ||
14-Day ATR (â‚©) | 773.507181 | ||
20-Day SMA (â‚©) | 19984.5 | ||
12-1 Month Momentum % | -0.49 | ||
52-Week Range (â‚©) | 17600 - 41200 | ||
Shares Outstanding (Mil) | 39.81 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Hyundai Bioscience Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Hyundai Bioscience Co Ltd Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Hyundai Bioscience Co Ltd Frequently Asked Questions
What is Hyundai Bioscience Co Ltd(XKRX:048410)'s stock price today?
When is next earnings date of Hyundai Bioscience Co Ltd(XKRX:048410)?
Does Hyundai Bioscience Co Ltd(XKRX:048410) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |